CNS Pharmaceuticals, Inc. Operating Expenses
CNS Pharmaceuticals, Inc. (CNSP) reported Operating Expenses of $2.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $2.70M, a 12.08% increase year-over-year.
- CNS Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $4.98M, a 14.70% increase year-over-year.
- CNS Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $5.99M, a 87.06% increase year-over-year.
- CNS Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $3.25M, a 42.20% decline year-over-year.
- CNS Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $15.99M, a 7.28% increase from fiscal 2024.
- CNS Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $14.90M, a 21.01% decline from fiscal 2023.
- CNS Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $18.87M, a 23.57% increase from fiscal 2022.
- CNS Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $15.27M, a 5.39% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-12 | $7.67M 10-Q · filed 2026-08-12 | $13.66M derived: sum of 3 quarters · filed 2026-08-12 | $16.91M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $4.98M 10-Q · filed 2026-05-14 | $10.96M derived: sum of 2 quarters · filed 2026-05-14 | $14.21M derived: sum of 3 quarters · filed 2026-05-14 | $16.62M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $5.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $9.24M derived: sum of 2 quarters · filed 2026-03-31 | $11.65M derived: sum of 3 quarters · filed 2026-08-12 | $15.99M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $3.25M 10-Q · filed 2025-11-14 | $5.66M derived: sum of 2 quarters · filed 2026-08-12 | $10.00M 10-Q · filed 2025-11-14 | $13.20M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $2.41M 10-Q · filed 2026-08-12 | $2.41M 10-Q · filed 2025-08-14 | $6.75M 10-Q · filed 2026-08-12 | $6.75M 10-Q · filed 2025-08-14 | $9.95M derived: sum of 3 quarters · filed 2026-08-12 | $15.58M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $4.34M 10-Q · filed 2026-05-14 | $7.54M derived: sum of 2 quarters · filed 2026-05-14 | $13.17M derived: sum of 3 quarters · filed 2026-05-14 | $15.69M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $8.83M derived: sum of 2 quarters · filed 2026-03-31 | $11.36M derived: sum of 3 quarters · filed 2026-03-31 | $14.90M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $5.63M 10-Q · filed 2025-11-14 | $8.16M derived: sum of 2 quarters · filed 2025-11-14 | $11.70M 10-Q · filed 2025-11-14 | $17.08M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | $2.53M 10-Q · filed 2025-08-14 | $6.07M 10-Q · filed 2025-08-14 | $11.45M derived: sum of 3 quarters · filed 2025-08-14 | $15.99M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $3.54M 10-Q · filed 2025-05-15 | $8.92M derived: sum of 2 quarters · filed 2025-05-15 | $13.46M derived: sum of 3 quarters · filed 2025-05-15 | $17.48M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $9.91M derived: sum of 2 quarters · filed 2025-03-31 | $13.94M derived: sum of 3 quarters · filed 2025-03-31 | $18.87M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $4.53M 10-Q · filed 2024-11-14 | $8.56M derived: sum of 2 quarters · filed 2024-11-14 | $13.49M 10-Q · filed 2024-11-14 | $18.62M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $4.03M 10-Q · filed 2024-08-14 | $8.95M 10-Q · filed 2024-08-14 | $14.09M derived: sum of 3 quarters · filed 2024-08-14 | $17.51M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $4.93M 10-Q · filed 2024-05-15 | $10.06M derived: sum of 2 quarters · filed 2024-05-15 | $13.48M derived: sum of 3 quarters · filed 2024-05-15 | $17.04M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $5.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $8.55M derived: sum of 2 quarters · filed 2024-04-01 | $12.12M derived: sum of 3 quarters · filed 2024-04-01 | $15.27M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $3.42M 10-Q · filed 2023-11-14 | $6.98M derived: sum of 2 quarters · filed 2023-11-14 | $10.13M 10-Q · filed 2023-11-14 | $9.77M 10-Q · filed 2022-11-10 | $13.38M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $3.56M 10-Q · filed 2023-08-14 | $6.71M 10-Q · filed 2023-08-14 | $6.35M 10-Q · filed 2022-08-12 | $9.97M derived: sum of 3 quarters · filed 2023-08-14 | $13.78M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | $3.15M 10-Q · filed 2023-05-15 | $2.78M 10-Q · filed 2022-05-13 | $6.40M derived: sum of 2 quarters · filed 2023-05-15 | $10.21M derived: sum of 3 quarters · filed 2023-05-15 | $14.03M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $7.06M derived: sum of 2 quarters · filed 2023-03-31 | $10.88M derived: sum of 3 quarters · filed 2023-03-31 | $14.49M 10-K · filed 2023-03-31 | $14.03M 10-K · filed 2022-03-03 | |||
| 2021-09-30 | $3.81M 10-Q · filed 2022-11-10 | $7.62M derived: sum of 2 quarters · filed 2022-11-10 | $11.23M 10-Q · filed 2022-11-10 | $14.24M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $3.81M 10-Q · filed 2022-08-12 | $7.42M 10-Q · filed 2022-08-12 | $10.42M derived: sum of 3 quarters · filed 2022-08-12 | $12.43M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $3.61M 10-Q · filed 2022-05-13 | $6.61M derived: sum of 2 quarters · filed 2022-05-13 | $8.62M derived: sum of 3 quarters · filed 2022-05-13 | $11.10M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $5.01M derived: sum of 2 quarters · filed 2022-03-03 | $7.49M derived: sum of 3 quarters · filed 2022-03-03 | $9.45M 10-K · filed 2022-03-03 | ||||
| 2020-09-30 | $2.01M 10-Q · filed 2021-11-12 | $4.48M derived: sum of 2 quarters · filed 2021-11-12 | $6.45M 10-Q · filed 2021-11-12 | $8.98M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $2.47M 10-Q · filed 2021-08-13 | $4.44M 10-Q · filed 2021-08-13 | $6.97M derived: sum of 3 quarters · filed 2021-08-13 | $7.66M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $1.97M 10-Q · filed 2021-05-13 | $4.49M derived: sum of 2 quarters · filed 2021-05-13 | $5.19M derived: sum of 3 quarters · filed 2021-05-13 | $5.61M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $3.22M derived: sum of 2 quarters · filed 2021-02-12 | $3.64M derived: sum of 3 quarters · filed 2021-02-12 | $3.83M 10-K · filed 2021-02-12 | ||||
| 2019-09-30 | $699.09K 10-Q · filed 2020-11-12 | $1.11M derived: sum of 2 quarters · filed 2020-11-12 | $1.31M 10-Q · filed 2020-11-12 | $1.52M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $415.06K 10-Q · filed 2020-08-10 | $610.15K 10-Q · filed 2020-08-10 | $818.74K derived: sum of 3 quarters · filed 2020-08-10 | $988.64K derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $195.09K 10-Q · filed 2020-05-15 | $403.67K derived: sum of 2 quarters · filed 2020-05-15 | $573.58K derived: sum of 3 quarters · filed 2020-05-15 | |||||
| 2018-12-31 | $208.58K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $378.49K derived: sum of 2 quarters · filed 2020-03-12 | $881.79K 10-K · filed 2020-03-12 | |||||
| 2018-09-30 | $169.91K 10-Q · filed 2019-12-20 | $673.20K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |